Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Tata Elxsi Ltd lost 5.44% today to trade at Rs 3499.1. The BSE Information Technology index is down 1.3% to quote at 27492.28. The index is up 0.13 % over last one month. Among the other constituents of the index, Zensar Technologies Ltd decreased 2.33% and Tata Consultancy Services Ltd lost 2.29% on the day. The BSE Information Technology index went down 25.37 % over last one year compared to the 6.51% fall in benchmark SENSEX.
Tata Elxsi Ltd has lost 14% over last one month compared to 0.13% gain in BSE Information Technology index and 1.22% rise in the SENSEX. On the BSE, 17011 shares were traded in the counter so far compared with average daily volumes of 32460 shares in the past one month. The stock hit a record high of Rs 6423.1 on 15 Jul 2025. The stock hit a 52-week low of Rs 3473.75 on 15 Jul 2026.
While EBITDA improved by 15.7% year-on-year (YoY) to Rs 216 crore, EBITDA margin was 21.2% in Q1 FY27 as against 20.9% in Q1 FY26.
Profit before tax in Q1 FY27 stood at Rs 232.5 crore, up by 18.4% from Rs 196.3 crore recorded in Q1 FY26.
On a quarter-on-quarter (QoQ) basis, Tata Elxsi’s revenue has grown by 2.7%, while net profit has declined by 22.58%.
Manoj Raghavan, CEO and managing director, Tata Elxsi, said: 'For the quarter, Tata Elxsi delivered a healthy performance with growth in our two primary verticals, supported by strong deal execution and continued momentum in large strategic engagements.
Our Transportation business reported a growth of 13.3% YoY, driven by accelerated OEM engagements and strategic wins in the off-road and aerospace segments.
In Media & Communications, we delivered another strong quarter, growing 22.2% YoY through continued ramp-up of key engagements and expanded programs with global operators, broadcasters and device OEMs.
Our Healthcare and Life Sciences business reported a growth of 1.7% QoQ, amidst a muted business environment for the healthcare industry.
FY27 marks a year of future focus for the company, as we prepare and equip ourselves for a world reshaped by AI. We are making targeted investments in specialized talent, AI powered platforms, tools and infrastructure, to pivot to a Domain + AI future.'
Tata Elxsi is amongst the world’s leading providers of design and technology services across industries including automotive, broadcast, communications, healthcare and transportation.
The scrip tumbled 4.96% to currently trade at Rs 3516.95 on the BSE.
KPIT had earlier warned that its Q1 FY27 USD reported revenue is likely to decline about 1% year-on-year, primarily due to sudden actions by several European original equipment manufacturers (OEMs) following recent profit warnings and a weaker business outlook. The company also said its EBITDA and net profit margins would decline sequentially.
The cautious commentary raised concerns over spending by global automotive clients, prompting investors to pare exposure to peers such as Tata Elxsi, which also derives a significant share of its revenue from automotive engineering and software services.
While KPIT expects the near-term weakness to be temporary and has reiterated confidence in a recovery during the second half of FY27, investors remained cautious about the outlook for the automotive technology sector.
Tata Elxsi is a global provider of design and technology services, with a strong presence in the automotive, broadcast, communications, healthcare and transportation sectors.
The company reported a 27.8% year-on-year increase in net profit to Rs 220.35 crore in Q4 FY26 from Rs 172.42 crore in Q4 FY25. Revenue from operations rose 9.4% to Rs 993.75 crore during the quarter ended 31 March 2026, compared with Rs 908.34 crore in the year-ago period.
Tata Elxsi announced the launch of AnaTel™, an AI-native software development platform for healthcare and medical technology companies, co-developed with OpenAna, a provider of autonomous AI engineering platforms. AnaTel™ makes its debut at DeviceTalks Boston 2026, where Tata Elxsi is presenting its latest advances in AI-powered MedTech engineering and compliance.
Healthcare and medtech software teams face a growing operational challenge. Regulatory expectations for AI-enabled device software are rising, with the FDA's 2025 draft guidance on AI-Enabled Device Software Functions and Europe's MDCG 2025-26 both requiring rigorous lifecycle documentation, traceability, and validation evidence as part of core engineering workflows, not submission afterthoughts. The result is a familiar bottleneck: requirements, test cases, traceability matrices, and regulatory artifacts are assembled manually across disconnected tools. Every software change becomes a documentation exercise. Every submission cycle starts from scratch.
AnaTel™ addresses this by embedding autonomous AI agents directly into the engineering workflow. Unlike developer productivity tools that focus on code generation alone, AnaTel™ operates across the full AI-Driven Software Delivery Lifecycle, from requirements and architecture through deployment, verification and validation, and continuous optimization, making it a true end-to-end engineering execution platform for regulated environments. Operating as a configurable AI software team, AnaTel™ generates code, documentation, test cases, and regulatory artifacts, drawing on a dedicated Healthcare and Life Sciences expert agent fine-tuned for medtech regulatory and engineering contexts. Human engineers and regulatory experts remain in control at every critical review and decision point. The platform supports eSTAR-aligned submission preparation, requirements traceability matrices, verification and validation evidence, and audit-trail documentation as part of day-to-day engineering. It is expected to reduce SaMD development and change assessment timelines from eight weeks to 72 hours, with productivity improvements of up to 60%.
AnaTel™ draws on Tata Elxsi's extensive experience building software in highly regulated medical device environments, engineering depth that has shaped how the platform reasons about traceability, validation, and compliance, not just how it is deployed.
Tata Elxsi brings design-led and AI-first engineering, deep domain expertise, and access to global healthcare and medtech enterprises; OpenAna brings platform and technology innovation.
Tata Elxsi announced the launch of ViTel™, a Material Intelligence solution for Medical Device manufacturers, co developed with Viridium AI, a material intelligence platform company. ViTel™ is being formally introduced at DeviceTalks Boston 2026, where Tata Elxsi is presenting its latest advances in AI-powered MedTech engineering and compliance.
Medical device manufacturers are facing a new operating reality. Material decisions now affect margin, resilience, product velocity, and market access, yet critical product knowledge remains buried across BOMs, supplier documents, ERP and PLM systems, and expert teams. This makes every new regulation or customer requirement a costly manual exercise.
ViTel™ addresses this by creating a reusable Material Intelligence layer across the enterprise, helping teams identify material and supplier dependencies, assess country-of-origin and sourcing exposure, evaluate alternatives, and understand where product or material risks affect cost, continuity, or market access. Powered by Viridium AI's Knowledge Cloud, Chemical Digital Twin, and science-constrained AI models, ViTel™ transforms scattered enterprise data into a living product-material knowledge graph connecting products, parts, materials, chemicals, suppliers, regulations, and evidence.
ViTel™ draws on Tata Elxsi's three decades of Med-Tech engineering and regulatory expertise, knowledge that has been embedded into how the solution reasons about material risk, compliance, and sourcing decisions, not just how it is deployed.
Tata Elxsi brings design-led and AI-first engineering, deep domain expertise, and access to global healthcare and medtech enterprises; Viridium AI brings platform and technology innovation.